Advertisement
About MicroRNA
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.
Advertisement
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs.Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The company expects that the first microRNA diagnostic tests applying itstechnology will be launched by licensed clinical laboratories in the UnitedStates in 2008.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the role of microRNAs in human physiology and disease, thepotential of microRNAs in the diagnosis and treatment of disease and theexpected timing of submission for approval and launch of diagnostic testsusing our microRNA technology constitute forward-looking statements for thepurposes of the safe harbor provisions under The Private SecuritiesLitigation Reform Act of 1995. Actual results may differ materially fromthose indicated by these forward-looking statements as a result of variousimportant factors, including risks related to: Rosetta's approach to discovermicroRNA technology and to work on the application of this technology in thedevelopment of novel diagnostics and therapeutic tools, which is unproven andmay never lead to marketable products or services; Rosetta's ability to fundand the results of further pre-clinical and clinical trials; Rosetta'sability to obtain, maintain and protect the intellectual property utilized byRosetta's products; Rosetta's ability to enforce its patents againstinfringers and to defend its patent portfolio against challenges from thirdparties; Rosetta's ability to obtain additional funding to support itsbusiness activities; Rosetta's dependence on third parties for development,manufacture, marketing, sales, and distribution of products; Rosetta'sability to successfully develop its candidate tools, products and services,all of which are in early stages of development; Rosetta's ability to obtainregulatory clearances or approvals that may be required for its products andservices; the ability to obtain coverage and adequate payment from healthinsurers for the products and services comprising Rosetta's technology;competition from others using technology similar to Rosetta's and othersdeveloping products for similar uses; Rosetta's dependence on collaborators;and Rosetta's short operating history; as well as those risks more fullydiscussed in the "Risk Factors" section of Rosetta's Annual Report on Form20-F for the year ended December 31, 2007 as filed with the Securities andExchange Commission. In addition, any forward-looking statements representRosetta's views only as of the date of this release and should not be reliedupon as representing its views as of any subsequent date. Rosetta does notassume any obligation to update any forward-looking statements unlessrequired by law.Media & Investors Ron Kamienchick T: +972-73-222-0730 E: [email protected]
SOURCE Rosetta Genomics Ltd
